SCHEMBL6418347

SCHEMBL6418347

N/N=C(\c1ccc(-c2ccc(O)c(C(=O)O)c2)o1)c1nc2nonc2nc1Nc1ccccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 7/20 0.40
LDHB P07195 6/20 0.40
ACMSD Q8TDX5 1/20 0.38
HAO1 Q9UJM8 5/20 0.38
BIRC5 O15392 1/20 0.37
AKT1 P31749 1/20 0.35
KMT2A Q03164 3/20 0.34
MCL1 Q07820 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NSD2 O96028 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
NR4A1 P22736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418358 1.00 LDHA (0.40) LDHALDHBACMSDHAO1BIRC5
SCHEMBL6416293 0.92 ALDH1A1 (0.41) BIRC5KMT2AMCL1NPC1RAB9A
SCHEMBL6435669 0.81 MAPT (0.44) KMT2AMCL1NPC1RAB9AMEN1
SCHEMBL6435995 0.79 BIRC5 (0.50) BIRC5KMT2AMCL1NPC1RAB9A
SCHEMBL6432253 0.79 RPA1 (0.44) KMT2AMCL1NPC1RAB9AMEN1
SCHEMBL6418352 0.79 BIRC5 (0.60) LDHALDHBHAO1BIRC5AKT1
SCHEMBL6433045 0.79 KDM4E (0.45) KMT2AMCL1NPC1RAB9AMEN1
SCHEMBL6422204 0.77 KDM4E (0.44) KMT2AMCL1NPC1RAB9AMEN1
SCHEMBL6415140 0.76 MAPT (0.42) KMT2AMCL1RAB9AMEN1KDM4E
SCHEMBL6414398 0.76 ALDH1A1 (0.43) LDHALDHBKMT2AMCL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 LDHA 3775/4885LDHB 4014/4885ACMSD 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.